NCT07284121 A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
| NCT ID | NCT07284121 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hoffmann-La Roche |
| Condition | Lung Cancer, Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2025-07-15 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
Eligibility Criteria
Inclusion Criteria: * Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC: * Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC * Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated * Extensive-stage small cell lung cancer (ES-SCLC) not previously treated * Advanced or unresectable HCC not previously treated with systemic therapy * Should not have received \> 4 prior cycles of IV Atezolizumab Exclusion Criteria: * Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling * Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label * Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program * Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life
Contact & Investigator
Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below.
✉ global-roche-genentech-trials@gene.com📞 888-662-6728 (U.S. and Canada)
Clinical Trials
STUDY DIRECTOR
Hoffmann-La Roche
Frequently Asked Questions
Who can join the NCT07284121 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer, Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07284121 currently recruiting?
Yes, NCT07284121 is actively recruiting participants. Contact the research team at global-roche-genentech-trials@gene.com for enrollment information.
Where is the NCT07284121 trial being conducted?
This trial is being conducted at Krems, Austria, Linz, Austria, Vienna, Austria, Wels, Austria and 11 additional locations.
Who is sponsoring the NCT07284121 clinical trial?
NCT07284121 is sponsored by Hoffmann-La Roche. The principal investigator is Clinical Trials at Hoffmann-La Roche. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.